Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation

Core Insights - Senti Biosciences, Inc. announced participation in a Virtual Investor CEO Connect Segment, highlighting its advancements in cell and gene therapies using the Gene Circuit platform [2][3] Group 1: FDA Designation and Clinical Trials - The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202, a potential first-in-class CAR-NK investigational cell therapy for relapsed/refractory hematologic malignancies, including AML [3] - SENTI-202 previously received Orphan Drug Designation from the FDA in June [3] - New data from a multinational clinical trial involving 20 patients (18 with evaluable responses) for SENTI-202 was presented at the American Society of Hematology (ASH) Annual Meeting [3] Group 2: Company Overview and Technology - Senti Bio is focused on developing next-generation cell and gene therapies for incurable diseases, utilizing a synthetic biology platform to engineer Gene Circuits [4] - The Gene Circuits are designed to selectively kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing for post-administration control [4] - The company's pipeline includes cell therapies targeting both liquid and solid tumors, with preclinical evidence supporting the efficacy of Gene Circuits in NK and T cells [4]